SI3356529T1 - Sestavki in postopki za zaviranje izražanja gena LPA - Google Patents
Sestavki in postopki za zaviranje izražanja gena LPAInfo
- Publication number
- SI3356529T1 SI3356529T1 SI201631374T SI201631374T SI3356529T1 SI 3356529 T1 SI3356529 T1 SI 3356529T1 SI 201631374 T SI201631374 T SI 201631374T SI 201631374 T SI201631374 T SI 201631374T SI 3356529 T1 SI3356529 T1 SI 3356529T1
- Authority
- SI
- Slovenia
- Prior art keywords
- procedures
- compositions
- gene expression
- lpa gene
- inhibiting lpa
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 101150091521 lpa gene Proteins 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562235816P | 2015-10-01 | 2015-10-01 | |
| US201662346304P | 2016-06-06 | 2016-06-06 | |
| US201662383221P | 2016-09-02 | 2016-09-02 | |
| EP16852695.2A EP3356529B1 (en) | 2015-10-01 | 2016-09-30 | Compositions and methods for inhibiting gene expression of lpa |
| PCT/US2016/054729 WO2017059223A2 (en) | 2015-10-01 | 2016-09-30 | Compositions and methods for inhibiting gene expression of lpa |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3356529T1 true SI3356529T1 (sl) | 2022-01-31 |
Family
ID=58424351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201631374T SI3356529T1 (sl) | 2015-10-01 | 2016-09-30 | Sestavki in postopki za zaviranje izražanja gena LPA |
Country Status (37)
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7718133B2 (en) | 2003-10-09 | 2010-05-18 | 3M Innovative Properties Company | Multilayer processing devices and methods |
| KR102348425B1 (ko) * | 2016-03-07 | 2022-01-10 | 애로우헤드 파마슈티컬스 인코포레이티드 | 치료용 화합물을 위한 표적화 리간드 |
| US10294474B2 (en) | 2016-09-02 | 2019-05-21 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands |
| EP3607069B1 (en) | 2017-04-05 | 2022-11-02 | Silence Therapeutics GmbH | Products and compositions |
| JP2020526192A (ja) * | 2017-07-06 | 2020-08-31 | アローヘッド ファーマシューティカルズ インコーポレイテッド | アルファ−ＥＮａＣの発現を阻害するためのＲＮＡｉ剤、および使用方法 |
| US10597657B2 (en) * | 2017-09-11 | 2020-03-24 | Arrowhead Pharmaceuticals, Inc. | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) |
| CN111343994B (zh) * | 2017-09-14 | 2023-11-21 | 箭头药业股份有限公司 | 用于抑制血管生成素-样3 (ANGPTL3)的表达的RNAi剂和组合物以及使用方法 |
| CN111655268B (zh) | 2017-10-04 | 2024-03-26 | 艾维迪提生物科学公司 | 核酸-多肽组合物及其用途 |
| AU2018352379A1 (en) * | 2017-10-17 | 2020-06-04 | Arrowhead Pharmaceuticals, Inc. | RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1 |
| KR102553382B1 (ko) * | 2017-11-13 | 2023-07-07 | 사일런스 테라퓨틱스 게엠베하 | 세포에서 lpa의 발현을 저해하기 위한 핵산 |
| EP3483270A1 (en) * | 2017-11-13 | 2019-05-15 | Silence Therapeutics GmbH | Products and compositions |
| MY209138A (en) * | 2018-09-19 | 2025-06-24 | Arrowhead Pharmaceuticals Inc | Rnai agents for inhibiting expression of 17beta-hsd type 13- (hsd17b13), compositions thereof, and methods of use |
| SI3880818T1 (sl) * | 2018-11-13 | 2023-01-31 | Silence Therapeutics Gmbh | Nukleinske kisline za inhibiranje izražanja LPA v celici |
| AU2020289464B2 (en) | 2019-06-06 | 2025-12-04 | Avidity Biosciences, Inc. | Nucleic acid-polypeptide compositions and uses thereof |
| WO2020257194A1 (en) * | 2019-06-17 | 2020-12-24 | Alnylam Pharmaceuticals, Inc. | Delivery of oligonucleotides to the striatum |
| CN112442499A (zh) * | 2019-08-30 | 2021-03-05 | 恩智（广州）医药科技有限公司 | 一种抑制MCM7的siRNA、组合物及其应用 |
| MX2022007005A (es) | 2019-12-09 | 2022-08-25 | Amgen Inc | Construcciones de iarn y metodos para inhibir la expresion de lpa. |
| EP4126967A1 (en) * | 2020-03-23 | 2023-02-08 | Amgen Inc. | Monoclonal antibodies to chemically-modified nucleic acids and uses thereof |
| JP7476422B2 (ja) | 2020-08-05 | 2024-04-30 | ディセルナ ファーマシューティカルズ インコーポレイテッド | Ｌｐａ発現を阻害するための組成物及び方法 |
| CN116490195A (zh) * | 2020-10-16 | 2023-07-25 | 赛诺菲 | 用于抑制脂蛋白(a)的RNA组合物和方法 |
| KR20230104200A (ko) * | 2020-11-05 | 2023-07-07 | 암젠 인크 | LPA-표적화된 RNAi 작제물을 이용하여 죽상경화성 심혈관질환을 치료하는 방법 |
| WO2022121959A1 (zh) * | 2020-12-09 | 2022-06-16 | 纳肽得有限公司 | siRNA分子及其在治疗冠状动脉疾病中的应用 |
| EP4237561A1 (en) | 2020-12-23 | 2023-09-06 | Argonaute Rna Limited | Treatment of cardiovascular disease |
| CN117836307A (zh) | 2021-06-18 | 2024-04-05 | 弘景生物科技有限公司 | 功能化的n-乙酰基半乳糖胺核苷 |
| JP2024532271A (ja) | 2021-08-30 | 2024-09-05 | ホンジーン バイオテック コーポレイション | 官能化ｎ－アセチルガラクトサミンアナログ |
| CA3229020A1 (en) | 2021-09-14 | 2023-03-23 | Stella Khan | Treatment of cardiovascular disease |
| EP4403633A1 (en) * | 2021-09-18 | 2024-07-24 | Genoval Therapeutics Co., Ltd. | Lpa inhibitor and use thereof |
| WO2023114746A1 (en) | 2021-12-15 | 2023-06-22 | Hongene Biotech Corporation | Functionalized n-acetylgalactosamine analogs |
| TW202340465A (zh) * | 2021-12-16 | 2023-10-16 | 大陸商上海拓界生物醫藥科技有限公司 | 靶向ｌｐａ的ｓｉｒｎａ及綴合物 |
| CN114703184B (zh) * | 2022-03-11 | 2024-06-18 | 厦门甘宝利生物医药有限公司 | Lpa抑制剂及其用途 |
| JP2025526074A (ja) * | 2022-08-11 | 2025-08-07 | エピジェニック・セラピューティクス・プライベイト・リミテッド | エピトープ編集標的のための方法およびその使用 |
| CN115851723B (zh) * | 2022-10-24 | 2023-10-03 | 厦门甘宝利生物医药有限公司 | 一种抑制lpa基因表达的rna抑制剂及其应用 |
| US12116382B2 (en) | 2022-11-28 | 2024-10-15 | Hongene Biotech Corporation | Functionalized N-acetylgalactosamine analogs |
| WO2024151937A1 (en) * | 2023-01-13 | 2024-07-18 | Eli Lilly And Company | Therapeutic oligonucleotide-containing pharmaceutical compositions and dosing regimens using the same |
| CN118773191A (zh) * | 2023-04-03 | 2024-10-15 | 翰森（上海）健康科技有限公司 | 靶向LPA基因的RNAi剂及其用途 |
| WO2024222686A1 (zh) * | 2023-04-24 | 2024-10-31 | 上海京新生物医药有限公司 | 用于抑制LPA表达的RNAi剂及其应用 |
| WO2024240212A1 (zh) * | 2023-05-24 | 2024-11-28 | 云合智药（苏州）生物科技有限公司 | 用于抑制angptl3表达的rnai剂及其应用 |
| AU2024280186A1 (en) * | 2023-05-31 | 2025-12-04 | Tuojie Biotech (Shanghai) Co., Ltd. | Dsrna targeting lpa and use thereof |
| WO2024249680A2 (en) * | 2023-05-31 | 2024-12-05 | Arrowhead Pharmaceuticals, Inc. | Hepatic Delivery Platforms For Multimeric RNAi Agent Conjugates and Methods of Use Thereof |
| DE102023115075A1 (de) * | 2023-06-07 | 2024-12-12 | B.Braun Avitum Ag | Schlauchrollenpumpe |
| WO2025064821A2 (en) | 2023-09-21 | 2025-03-27 | Ionis Pharmaceuticals, Inc. | Compounds and methods for inhibiting lpa |
| WO2025082058A1 (zh) * | 2023-10-16 | 2025-04-24 | 润佳(上海)医药技术有限公司 | 一种抑制LPA基因表达的dsRNA及其用途 |
| CN120344664A (zh) * | 2023-10-27 | 2025-07-18 | 北京安龙生物医药有限公司 | 靶向脂蛋白a的寡核苷酸及其用途 |
| WO2025103391A1 (zh) * | 2023-11-15 | 2025-05-22 | 北京加科瑞康医药科技有限公司 | 用于抑制lpa的基因表达的sirna，含其的组合物及其用途 |
| CN120020252A (zh) * | 2023-11-17 | 2025-05-20 | 纳肽得(青岛)生物医药有限公司 | 抑制LPA表达的siRNA及其用途 |
| CN120098993A (zh) * | 2023-12-05 | 2025-06-06 | 广东东阳光药业股份有限公司 | 一种新型的双链siRNA、其缀合物及其用途 |
| CN120485189B (zh) * | 2025-07-16 | 2025-10-17 | 北京悦康科创医药科技股份有限公司 | 靶向调控LPA基因表达的siRNA及其用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| US5599706A (en) | 1994-09-23 | 1997-02-04 | Stinchcomb; Dan T. | Ribozymes targeted to apo(a) mRNA |
| EP1159441B8 (en) | 1999-03-10 | 2008-10-29 | Marie Curie Cancer Care | Delivery of nucleic acids and proteins to cells |
| DK1407044T4 (en) * | 2000-12-01 | 2017-12-04 | Max-Planck-Gesellschaft Zur Förderung Der Wss E V | RNA interference mediating small RNA molecules |
| US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
| US7259150B2 (en) | 2001-08-07 | 2007-08-21 | Isis Pharmaceuticals, Inc. | Modulation of apolipoprotein (a) expression |
| EP1613348B1 (en) | 2003-03-12 | 2010-06-23 | The Arizona Board of Regents on Behalf of the University of Arizona | Methods for modulating angiogenesis with apelin compositions |
| CA2559955C (en) | 2004-03-15 | 2016-02-16 | City Of Hope | Methods and compositions for the specific inhibition of gene expression by double-stranded rna |
| EP2061443A4 (en) * | 2006-08-18 | 2013-07-24 | Arrowhead Res Corp | POLYCONJUGATE FOR IN VIVO ADMINISTRATION OF POLYNUCLEOTIDES |
| AU2009336191B2 (en) | 2008-12-18 | 2017-08-24 | Novo Nordisk A/S | Extended dicer substrate agents and methods for the specific inhibition of gene expression |
| US20100249214A1 (en) | 2009-02-11 | 2010-09-30 | Dicerna Pharmaceuticals | Multiplex dicer substrate rna interference molecules having joining sequences |
| JP6137834B2 (ja) | 2010-02-24 | 2017-05-31 | アローヘッド ファーマシューティカルズ インコーポレイテッド | ｓｉＲＮＡの標的化送達のための組成物 |
| US8865675B2 (en) * | 2010-05-12 | 2014-10-21 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein B |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| US9249179B2 (en) * | 2010-12-17 | 2016-02-02 | Arrowhead Madison Inc. | Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA |
| WO2012092373A2 (en) | 2010-12-29 | 2012-07-05 | Arrowhead Research Corporation | In vivo polynucleotide delivery conjugates having enzyme sensitive linkages |
| CA2842039A1 (en) | 2011-08-26 | 2013-03-07 | Arrowhead Research Corporation | Poly(vinyl ester) polymers for in vivo nucleic acid delivery |
| PT3301177T (pt) * | 2011-11-18 | 2020-06-29 | Alnylam Pharmaceuticals Inc | Agentes de arni, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr) |
| US8933047B2 (en) | 2012-04-18 | 2015-01-13 | Arrowhead Madison Inc. | Poly(acrylate) polymers for in vivo nucleic acid delivery |
| RU2624028C2 (ru) | 2012-05-24 | 2017-06-30 | Ионис Фармасьютикалз, Инк. | Способы и композиции для модулирования экспрессии аполипопротеина (а) |
| WO2014134483A2 (en) * | 2013-02-28 | 2014-09-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| CN105378082B (zh) * | 2013-05-01 | 2020-06-09 | Ionis制药公司 | 组合物和方法 |
| WO2016149020A1 (en) * | 2015-03-17 | 2016-09-22 | Arrowhead Research Corporation | Rna interference agents |
| MX2017014641A (es) | 2015-05-29 | 2018-01-23 | Arrowhead Pharmaceuticals Inc | Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa). |
| SMT202100020T1 (it) * | 2015-07-31 | 2021-03-15 | Alnylam Pharmaceuticals Inc | Composizioni di irna di transtiretina (ttr) e relativi metodi d'uso per trattare o prevenire malattie associate a ttr |
| KR102348425B1 (ko) | 2016-03-07 | 2022-01-10 | 애로우헤드 파마슈티컬스 인코포레이티드 | 치료용 화합물을 위한 표적화 리간드 |
-
2015
- 2015-10-01 JO JOP/2021/0043A patent/JOP20210043A1/ar unknown
-
2016
- 2016-09-28 JO JOP/2016/0211A patent/JOP20160211B1/ar active
- 2016-09-30 PT PT168526952T patent/PT3356529T/pt unknown
- 2016-09-30 IL IL300438A patent/IL300438A/en unknown
- 2016-09-30 JP JP2018516738A patent/JP6991966B2/ja active Active
- 2016-09-30 SI SI201631374T patent/SI3356529T1/sl unknown
- 2016-09-30 HR HRP20211410TT patent/HRP20211410T1/hr unknown
- 2016-09-30 UA UAA201804593A patent/UA121998C2/uk unknown
- 2016-09-30 TW TW105131823A patent/TWI784934B/zh active
- 2016-09-30 MY MYPI2018000440A patent/MY195796A/en unknown
- 2016-09-30 CR CR20180231A patent/CR20180231A/es unknown
- 2016-09-30 MX MX2018003833A patent/MX2018003833A/es unknown
- 2016-09-30 HU HUE16852695A patent/HUE055942T2/hu unknown
- 2016-09-30 BR BR112018006489-0A patent/BR112018006489A2/pt active Search and Examination
- 2016-09-30 KR KR1020247036942A patent/KR20240162596A/ko active Pending
- 2016-09-30 WO PCT/US2016/054729 patent/WO2017059223A2/en not_active Ceased
- 2016-09-30 SM SM20210622T patent/SMT202100622T1/it unknown
- 2016-09-30 ES ES16852695T patent/ES2896298T3/es active Active
- 2016-09-30 CN CN201680057095.8A patent/CN108368506A/zh active Pending
- 2016-09-30 KR KR1020187010095A patent/KR102728481B1/ko active Active
- 2016-09-30 TW TW113106862A patent/TWI880645B/zh active
- 2016-09-30 CA CA3000397A patent/CA3000397A1/en active Pending
- 2016-09-30 RS RS20211351A patent/RS62523B1/sr unknown
- 2016-09-30 SG SG10202008530TA patent/SG10202008530TA/en unknown
- 2016-09-30 EA EA201890864A patent/EA038478B1/ru unknown
- 2016-09-30 EP EP21191363.7A patent/EP4029941A1/en active Pending
- 2016-09-30 LT LTEPPCT/US2016/054729T patent/LT3356529T/lt unknown
- 2016-09-30 EP EP16852695.2A patent/EP3356529B1/en active Active
- 2016-09-30 PL PL16852695T patent/PL3356529T3/pl unknown
- 2016-09-30 US US15/281,309 patent/US9932586B2/en active Active
- 2016-09-30 PE PE2018000487A patent/PE20181139A1/es unknown
- 2016-09-30 TN TNP/2018/000094A patent/TN2018000094A1/en unknown
- 2016-09-30 AU AU2016331084A patent/AU2016331084B2/en active Active
- 2016-09-30 TW TW111141660A patent/TWI836693B/zh active
- 2016-09-30 DK DK16852695.2T patent/DK3356529T3/da active
- 2016-09-30 UY UY0001036926A patent/UY36926A/es active IP Right Grant
-
2017
- 2017-04-06 MA MA43347A patent/MA43347B1/fr unknown
-
2018
- 2018-02-21 US US15/901,810 patent/US10662427B2/en active Active
- 2018-03-25 IL IL258333A patent/IL258333B/en unknown
- 2018-03-27 MX MX2022013010A patent/MX2022013010A/es unknown
- 2018-03-28 CL CL2018000803A patent/CL2018000803A1/es unknown
- 2018-03-28 PH PH12018500713A patent/PH12018500713A1/en unknown
- 2018-04-05 CO CONC2018/0003678A patent/CO2018003678A2/es unknown
-
2020
- 2020-05-06 US US16/867,925 patent/US20200263179A1/en not_active Abandoned
-
2021
- 2021-03-12 JP JP2021039949A patent/JP7116212B2/ja active Active
- 2021-08-30 ZA ZA2021/06265A patent/ZA202106265B/en unknown
- 2021-11-08 CY CY20211100962T patent/CY1125263T1/el unknown
-
2022
- 2022-02-13 IL IL290566A patent/IL290566B2/en unknown
- 2022-06-15 JP JP2022096415A patent/JP7442574B2/ja active Active
- 2022-12-05 AU AU2022283623A patent/AU2022283623B2/en active Active
-
2023
- 2023-11-27 JP JP2023199857A patent/JP2024009262A/ja not_active Withdrawn
-
2024
- 2024-06-17 US US18/745,289 patent/US20250115907A1/en active Pending
-
2025
- 2025-10-03 AU AU2025242219A patent/AU2025242219A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3356529T1 (sl) | Sestavki in postopki za zaviranje izražanja gena LPA | |
| PL3386534T3 (pl) | Kompozycje i sposoby internalizacji enzymów | |
| EP3673055A4 (en) | RNA TARGETING METHODS AND COMPOSITIONS | |
| HUE063026T2 (hu) | Eljárások és készítmények LDHA expressziójának gátlására | |
| EP3523437A4 (en) | Oligonucleotide compositions and methods thereof | |
| EP3548625C0 (en) | COMPOSITIONS AND METHODS FOR ACTIVATING GENE EXPRESSION | |
| EP3324978A4 (en) | Oligonucleotide compositions and methods thereof | |
| ME03003B (me) | Kompozicije koje sadrže bakterijske sojeve | |
| ZA201900225B (en) | Methods and compositions for gene expression in plants | |
| EP3322297C0 (en) | ADMINISTRATION METHODS AND COMPOSITIONS FOR NUCLEASE-MEDIATED GENOME ENGINEERING | |
| DK3274430T3 (da) | Mikroalgesammensætninger og deres anvendelser | |
| KR20180084891A (ko) | 구조 조성물 및 방법 | |
| EP3800191C0 (en) | Compositions and methods for improving gene expression in retinal cones | |
| CY2020029I1 (el) | Συνθεσεις και μεθοδοι για την αναστολη της εκφρασης του γονιδιου alas1 | |
| PL3500255T3 (pl) | Farmaceutyczne kompozycje okulistyczne i powiązane z nimi zastosowania | |
| SI3200815T1 (sl) | Postopki in sestavki za zdravljenje raka | |
| EP3273950A4 (en) | ADJUVANE COMPOSITIONS AND RELATED METHODS | |
| IL255998A (en) | Preparations and methods for suppressing the expression of the hif2alpha strain | |
| IL257524A (en) | Short interfering RNA and its use in methods and preparations for inhibiting the expression of ankyrin horseradish protein gene regulated by Nutz | |
| EP3349748A4 (en) | COMPOSITION AND METHOD THEREFOR | |
| DK3288536T3 (da) | Sammensætninger omfattende anakinra | |
| EP3317365A4 (en) | Microbial viscosity breaker compositions | |
| PL3191080T3 (pl) | Kompozycje pozajelitowe i ich zastosowanie | |
| DK3334281T3 (da) | Antimikrobielle sammensætninger indeholdende alkylpyraziner og deres anvendelser | |
| TH1501007482B (th) | สารกำจัดไบโอฟิล์มในช่องปากและองค์ประกอบที่ใช้สำหรับช่องปาก |